rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KYMR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data

      Kymera Therapeutics has delivered very strong share-price gains in recent years, and that kind of move naturally raises the question of whether the current valuation is still grounded in its underlying book value. With the stock now in a very different place than it was a few years ago, investors are asking how much of the story is already reflected on the balance sheet. Over the past 3 years the share price has climbed by more than 7x. That puts real weight on the question of how its...

      Nov 5Yahoo FinanceKYMR
      Kymera Therapeutics stock hits all-time high at 130.48 USD
      Nov 3Investing.comKYMR
      S&P 500 Futures Climb in Premarket Trading; Moog, Kymera Therapeutics Lead
      Nov 2Barron'sKYMRMOG.AMOG.B
      Kymera Therapeutics Inc (KYMR) (Q3 2026) Earnings Call Highlights: Strong Phase 1 Data and $1. ...
      Oct 29Yahoo FinanceKYMR
      Kymera Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Oct 29Yahoo FinanceKYMR
      Kymera (KYMR) Q3 2026 Earnings Call Transcript
      Oct 29The Globe and MailKYMR
      Oppenheimer raises Kymera Therapeutics price target on drug data
      Oct 29Investing.comKYMR
      Kymera Therapeutics Q3 Earnings Call Highlights
      Oct 29Yahoo FinanceKYMR
      Brookline Capital raises Kymera Therapeutics price target on reduced risk
      Oct 29Investing.comKYMR
      Kymera earnings missed by $0.05, revenue fell short of estimates
      Oct 29Investing.comKYMR
      Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement
      Oct 29Investing.comKYMR
      Kymera Therapeutics Q3 Net Loss Widens
      Oct 29Yahoo FinanceKYMR
      Kymera reports phase 1 data for KT-579, plans lupus trial
      Oct 29Investing.comKYMR
      Kymera to report Phase 1 trial results for KT-579 on Thursday
      Oct 28Investing.comKYMR
      Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

      WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video confe

      Oct 28Yahoo FinanceKYMR
      Kymera earnings on deck with atopic dermatitis drug in focus
      Oct 28Investing.comKYMR
      Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?
      Oct 27Yahoo FinanceKYMR
      Could You Have Seen The Run In Kymera Stock Coming?
      Oct 26Yahoo FinanceKYMR
      Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
      Oct 22Yahoo FinanceKYMR
      Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
      Oct 19Yahoo FinanceKYMR
      Nurix Therapeutics: Bexobrutideg Advancing Together With Roche, Kymera’s STAT6 Degrader Data Coming Up
      Oct 13Seeking AlphaKYMRNRIX
      Kymera Stock: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon (KYMR)

      Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitis—upside vs. Dupixent. See more here.

      Oct 9Seeking AlphaKYMR
      Raymond James initiates Kymera Therapeutics stock coverage with outperform rating
      Oct 8Investing.comKYMR
      Citi raises Kymera Therapeutics stock price target on drug potential
      Oct 5Investing.comKYMR
      Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock
      Oct 1Investing.comKYMR
      B.Riley reiterates Kymera Therapeutics stock rating on new trial data
      Oct 1Investing.comKYMRRILYRILYGRILYLRILYNRILYTRILYZ
      Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
      Sep 30MorningstarKYMR
      Kymera Therapeutics at Stifel forum: faster path for lead drug
      Sep 24Investing.comKYMRSF
      Goldman Sachs resumes Kymera Therapeutics stock coverage
      Sep 24Investing.comKYMR
      Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailKYMR
      Piper Sandler reiterates Kymera Therapeutics stock rating at $140
      Sep 23Investing.comKYMR
      Stifel raises Kymera Therapeutics price target on drug trial outlook
      Sep 22Investing.comKYMR
      Kymera Therapeutics at Morgan Stanley conference: oral degrader push
      Sep 15Investing.comKYMRMS
      Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Intuitive Surgical (ISRG)

      Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailKYMR
      Kymera Therapeutics at H.C. Wainwright: oral drug push gains pace
      Sep 14Investing.comKYMR
      BofA raises Kymera Therapeutics price target on trial progress
      Sep 14Investing.comKYMR
      BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

      Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $137.73, according

      Sep 14Yahoo FinanceKYMR
      Kymera Therapeutics at citigroup summit: oral immunology push gains pace
      Sep 10Investing.comKYMRC
      Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace
      Sep 9Investing.comKYMRWFC
      Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock
      Sep 4Investing.comKYMR
      Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

      Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 4Yahoo FinanceKYMR
      Can KT-621 Mark a Turning Point for Kymera Therapeutics?

      KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.

      Sep 3Yahoo FinanceKYMR
      Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

      Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailKYMRVTVT
      Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

      Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly

      Sep 2Yahoo FinanceKYMR
      Kymera Therapeutics to Participate in Upcoming September Investor Conferences

      WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET;Citi 2026 Biopharma Back to School Summit in New Yor

      Sep 2Yahoo FinanceKYMR
      Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program
      Aug 31Investing.comKYMR
      Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

      Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailKYMR

      This is the newest page. Registered accounts read further back.